Additional Abstracts of Interest in Multiple Myeloma at ASH 2015 | Research To Practice
Carfilzomib May Offer Advantages in Patients with Relapsed/Refractory Multiple Myeloma - The ASCO Post
Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment | Blood Cancer Journal
Elotuzumab - A Closer Look At The ELOQUENT-2 Clinical Trial Results
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma | NEJM
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma | NEJM
ASPIRE Trial - KRd VS Rd - Multiple Myeloma Clinical Trials
Carfilzomib Benefits Outweigh Potential for Cardiac Toxicity in Relapsed/Refractory Myeloma
Carfilzomib in multiple myeloma
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma | NEJM
Current Oncology | Free Full-Text | Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse
Takeda Oncology on Twitter: "Multiple #myeloma may be the most common, but DYK there are several other forms of myeloma? Take action, learn more https://t.co/aDKofURa4c https://t.co/aFizSxMTn0" / Twitter
Additional Abstracts of Interest in Multiple Myeloma at ASH 2015 | Research To Practice
Kyprolis Label to Include Positive Data of Aspire Trial in Advanced Multiple Myeloma Patients
![The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial - The](https://www.thelancet.com/cms/attachment/2f9746ff-a56a-4d1f-9fa7-5e6b9f11a6ee/gr1_lrg.jpg "The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial - The")
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial - The
Myeloma Update -- Part 1: Carfilzomib and Panobinostat
Updates from ASPIRE and ENDEAVOR: Multicenter phase III studies of carfilzomib for relapsed/refractory multiple myeloma - ecancer
Amgen's Phase III ASPIRE trial of myeloma treatment Kyprolis meets primary endpoint - Clinical Trials Arena
Frontiers | Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
Design of randomized phase 3 trials. A, ASPIRE trial; B, ENDEAVOR... | Download Scientific Diagram
Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR - ScienceDirect
Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials - ScienceDirect
Progression-free and overall survival for high-risk patients with relapsed or refractory multiple myeloma (RRMM) who received carfilzomib-based regimens
Cancer Trial Results
